DELIVERED SIGNIFICANT IMPROVEMENT IN EASI SCORES

75% IMPROVEMENT IN LESION EXTENT AND SEVERITY
(EASI-75*) AT WEEK 81,2

75% IMPROVEMENT IN LESION EXTENT AND SEVERITY (EASI-75*) AT WEEK 81,2

Adapted from Papp K et al. doi:10.17632/ffx6nd5zyb.1. Licensed under CC BY 4.0.

>60% of patients

achieved EASI-75 at week 81

>60% of patients

achieved EASI-75 at week 81

Patient Henry

Mild defined as EASI score 1.1–7.0.3

In TRuE-AD1 and TRuE-AD2, respectively, 46% and 50% of patients on OPZELURA vs 56% and 44% of patients on vehicle had a baseline EASI score of 1.1–7.0.4

*EASI-75 is defined as the achievement of at least 75% improvement in EASI score from baseline.1

BID=twice daily; EASI=Eczema Area and Severity Index.

Patient Henry

See safety results >

References: 1. Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. Published online May 3, 2021. doi:10.1016/j.jaad.2021.04.085. 2. Papp K, Szepietowski JC, Kircik L, et al. Supplementary appendix, efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase 3, randomized, double-blind studies. Mendeley Data. doi:10.17632/ffx6nd5zyb.1. 3. Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353-1357. 4. Data on file. Incyte Corporation. 2021.

improvement IN LESION EXTENT AND SEVERITY (EASI) AT WEEK 81

>70% mean improvement

in EASI score from baseline at week 81

>70% mean improvement

in EASI score from baseline at week 81

Patient Henry

Mild defined as EASI score 1.1–7.0.3

In TRuE-AD1 and TRuE-AD2, respectively, 46% and 50% of patients on OPZELURA vs 56% and 44% of patients on vehicle had a baseline EASI score of 1.1–7.0.4

BID=twice daily; EASI=Eczema Area and Severity Index.

Patient Henry

See safety results >

References: 1. Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. Published online May 3, 2021. doi:10.1016/j.jaad.2021.04.085. 2. Papp K, Szepietowski JC, Kircik L, et al. Supplementary appendix, efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase 3, randomized, double-blind studies. Mendeley Data. doi:10.17632/ffx6nd5zyb.1. 3. Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353-1357. 4. Data on file. Incyte Corporation. 2021.